ADMA Biologics, Inc.
ADMA
$20.46
$0.824.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 800.00% | 398.49% | 186.34% | 92.36% | 57.15% |
| Total Depreciation and Amortization | -3.44% | 0.51% | 5.34% | 11.34% | 17.01% |
| Total Amortization of Deferred Charges | -63.34% | -39.79% | -28.00% | 2.33% | 8.37% |
| Total Other Non-Cash Items | -291.68% | 275.74% | 290.82% | 304.99% | 138.92% |
| Change in Net Operating Assets | -83.14% | -108.72% | 59.33% | -14.26% | 44.64% |
| Cash from Operations | 1,248.55% | 631.98% | 276.16% | 144.19% | 114.79% |
| Capital Expenditure | -72.42% | 8.96% | 35.98% | 60.25% | 65.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -66.19% | -- | -- | -- | -- |
| Cash from Investing | -72.15% | 1.23% | 30.72% | 58.52% | 64.19% |
| Total Debt Issued | -- | -- | -- | -- | -11.04% |
| Total Debt Repaid | 62.17% | -763,402.02% | -467,702.36% | -428,524.32% | -58.54% |
| Issuance of Common Stock | 578.80% | -89.29% | -96.95% | -96.71% | -98.30% |
| Repurchase of Common Stock | -251.31% | -48.58% | -10.53% | 5.70% | 51.19% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 94.53% | -15,076,900.00% | -3,625.48% | -3,625.48% | -215.21% |
| Cash from Financing | -49.53% | -205.61% | -165.68% | -165.30% | -135.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 247.27% | -68.03% | 154.81% | -7,838.50% | -199.26% |